Crescent Biopharma, Inc. (CBIO): R&D Expense
$138.09M
Year ended 2025-12-31
$152.67M
Trailing 12 months to 2026-06-30
+69.4%
3-year compound annual growth
+25.2%
5-year compound annual growth
+18.6%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $138.09M | +868.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $14.26M | -29.0% | 2025-02-13, From 2024-01-01 |
| 2023-12-31 | $20.07M | -29.3% | 2025-02-13, From 2023-01-01 |
| 2022-12-31 | $28.39M | -40.2% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $47.49M | +5.7% | 2024-03-27, From 2021-01-01 |
| 2020-12-31 | $44.93M | -4.5% | 2023-03-29, From 2020-01-01 |
| 2019-12-31 | $47.03M | +17.3% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $40.09M | +66.4% | 2021-03-02, From 2018-01-01 |
| 2017-12-31 | $24.10M | +3.5% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $23.28M | -7.1% | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | $25.05M | +28.0% | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $19.57M | +67.3% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $11.70M | +24.0% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $9.44M | n/a | 2015-03-16, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $138.09M | +868.4% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $24.97M | +50.9% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $125.90M | +84.1% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $168.06M | +20.8% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $94.30M | -20.1% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $41.33M | -22.1% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $134.85M | -39.4% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $313.0K | -52.4% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $684.0K | +4.1% |
Compare CBIO, JAGX, JANX, ZBIO side by side · Screen every company in Pharmaceutical Preparations ↗